Panax notoginseng saponins promote osteogenic differentiation of bone marrow stromal cells through the ERK and P38 MAPK signaling pathways

Cellular Physiology and Biochemistry

Volumn 28, Issue 2, 2011, Pages 367-376

  Li, Xue Dong ^a   Liu, Zhao Yong ^a   Chang, Bo ^a   Liu, Dong Xin ^a   Chen, Bin ^a   Guo, Chun ^a   Wang, Yun Guo ^a   Xu, Jian Kun ^a   Huang, Dong Yang ^a   Du, Shi Xin ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Bone marrow stromal cells; Mitogen activated protein kinase (MAPK); Osteogenic differentiation; Osteoporosis; Panax notoginseng saponins

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALIZARIN RED S; ALKALINE PHOSPHATASE; BONE SIALOPROTEIN; GINSENG SAPONIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PANAX NOTOGINSENG SAPONIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; BONE MARROW STROMA CELL; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL PROLIFERATION; IN VITRO STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PANAX NOTOGINSENG; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STROMA CELL;

PANAX NOTOGINSENG;

EID: 80052086487     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000331753     Document Type: Article

References (50)

1. Raisz LG: Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115:3318-3325. (Pubitemid 43121814)
2. Deal C: Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol 2009;5:20-27.
3. Songlin P, Ge Z, Yixin H, Xinluan W, Pingchung L, Kwoksui L, Ling Q: Epimedium-derived flavonoids promote osteoblastogenesis and suppress adipogenesis in bone marrow stromal cells while exerting an anabolic effect on osteoporotic bone. Bone 2009;45:534-544.
4. Zhang JF, Li G, Chan CY, Meng CL, Lin MC, Chen YC, He ML, Leung PC, Kung HF: Flavonoids of Herba Epimedii regulate osteogenesis of human mesenchymal stem cells through BMP and Wnt/beta-catenin signaling pathway. Mol Cell Endocrinol 2010;314:70-74.
5. Shifren JL, Schiff I: Role of hormone therapy in the management of menopause. Obstet Gynecol 2010;115:839-855.
6. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-1662. (Pubitemid 41672231)
7. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK: Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137. (Pubitemid 44050394)
8. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R: PEARL Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-696.
9. Licata AA: Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 2005;39:668-677. (Pubitemid 40396621)
10. Rotella DP: Osteoporosis: challenges andnewopportunities for therapy. Curr Opin Drug Discov Devel 2002;5:477-486.
11. Armamento-Villareal R, Napoli N, Panwar V, Novack D: Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006;355:2048-2050. (Pubitemid 44708036)
12. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY: Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-1301. (Pubitemid 40463979)
13. Egermann M, Schneider E, Evans CH, Baltzer AW: The potential of gene therapy for fracture healing in osteoporosis. Osteoporos Int 2005;16:S120-128. (Pubitemid 46232129)
14. Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-74. (Pubitemid 27161245)
15. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147. (Pubitemid 29282067)
16. Meunier P, Aaron J, Edouard C, Vingnon G: Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res 1971;80:147-154.
17. Burkhardt R, Kettner G, Böhm W, Schmidmeier M, Schlag R, Frisch B, Mallmann B, Eisenmenger W, Gilg T: Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study. Bone 1987;8:157-164. (Pubitemid 17111858)
18. Verma S, Rajaratnam JH, Denton J, Hoyland JA, Byers RJ: Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol 2002;55:693-698. (Pubitemid 34970093)
19. Ng TB: Pharmacological activity of sanchi ginseng (Panax notoginseng). J Pharm Pharmacol 2006;58:1007-1719.
20. Chen W, Dang Y, Zhu C: Simultaneous determination of three major bioactive saponins of Panax notoginseng using liquid chromatography-tandem mass spectrometry and a pharmacokinetic study. Chin Med 2010;5:12.
21. Chen XC, Zhou YC, Chen Y, Zhu YG, Fang F, Chen LM: Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Acta Pharmacol Sin 2005;26:56-62. (Pubitemid 40093241)
22. Rhule A, Navarro S, Smith JR, Shepherd DM: Panax notoginseng attenuates LPSinduced pro-inflammatory mediators in RAW264.7 cells. J Ethnopharmacol 2006;106:121-128.
23. Gong YS, Chen J, Zhang QZ, Zhang JT: Effect of 17beta-oestradiol and ginsenoside on osteoporosis in ovariectomised rats. J Asian Nat Prod Res 2006;8:649-656. (Pubitemid 44884805)
24. Lu XZ, Wang JH, Wu X, Zhou L, Wang L, Zhang XW, Cao KJ, Huang J: Ginsenoside Rg1 promotes bone marrow stromal cells proliferation via the activation of the estrogen receptormediated signaling pathway. Acta Pharmacol Sin 2008;29:1209-1214.
25. Chang CH, Liao TC, Hsu YM, Fang HW, Chen CC, Lin FH: A poly(propylene fumarate)-calcium phosphate based angiogenic injectable bone cement for femoral head osteonecrosis. Biomaterials 2010;31:4048-4055.
26. Li XD, Wan JS, Chang B, Chen B,Guo C, Hou GQ, Huang DY, Du SX: Panax notoginseng saponins promotes proliferation and osteogenic differentiation of rat bone marrow stromal cells. J Ethnopharmacol 2011;134:268-274.
27. Li XD, Chang B, Chen B, Liu ZY, Liu DX, Wang JS, Hou GQ, Huang DY, Du SX: Panax notoginseng saponins potentiate osteogenesis of bone marrow stromal cells by modulating gap junction intercellular communication activities. Cell Physiol Biochem 2010;26:1081-1092.
28. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-183. (Pubitemid 32458157)
29. Johnson GL, Lapadat R: Mitogenactivated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:191-192.
30. Jaiswal RK, Jaiswal N, Bruder SP, Mbalaviele G, Marshak DR, Pittenger MF: Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated bymitogen-activated protein kinase. J Biol Chem 2000;275:9645-9652. (Pubitemid 30185197)
31. Sale EM, Atkinson PG, Sale GJ: Requirement of MAP kinase for differentiation of fibroblasts to adipocytes, for insulin activation of p90 S6 kinase and for insulin or serum stimulation of DNA synthesis. EMBO J 1995;14:674-684.
32. Fu L, Tang T, Miao Y, Zhang S, Qu Z, Dai K: Stimulation of osteogenic differentiation and inhibition of adipogenic differentiation in bone marrow stromal cells by alendronate via ERK and JNK activation. Bone 2008;43:40-47.
33. Oliveira JM, Sousa RA, Kotobuki N, Tadokoro M, Hirose M, Mano JF, Reis RL, Ohgushi H: The osteogenic differentiation of rat bone marrow stromal cells cultured with d e x a m e t h a s o n e-l o a d e d c a r b o x y m e t h y l c h i t o s a n/p o l y (amidoamine) dendrimer nanoparticles. Biomaterials 2009;30:804-813.
34. Li SH, Guo DZ, Li B, Yin HB, Li JK, Xiang JM, Deng GZ: The stimulatory effect of insulin-like growth factor-1 on the proliferation, differentiation, and mineralisation of osteoblastic cells from Holstein cattle. Vet J 2009;179:430-436.
35. Guan CC, Yan M, Jiang XQ, Zhang P, Zhang XL, Li J, Ye DX, Zhang FQ: Sonic hedgehog alleviates the inhibitory effects of high glucose on the osteoblastic differentiation of bone marrow stromal cells. Bone 2009;45:1146-1152.
36. Krause U, Harris S, Green A, Ylostalo J, Zeitouni S, Lee N, Gregory CA: Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proc Natl Acad Sci USA 2010;107:4147-4152.
37. Rodriguez JP, Garat S, Gajardo H, Pino AM, Seitz G: Abnormal steogenesis in osteoporotic patients is reflected by altered mesenchymal stem cells dynamics. J Cell Biochem 1999;75:414-423. (Pubitemid 29521650)
38. Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP: Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem 1997;64:295-312. (Pubitemid 27065443)
39. Rasmussen TP: Embryonic stem cell differentiation: a chromatin perspective. Reprod Biol Endocrinol 2003;1:100.
40. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G: Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 1997;89:747-754. (Pubitemid 27516177)
41. Harada H, Tagashira S, Fujiwara M, Ogawa S, Katsumata T, Yamaguchi A, Komori T, Nakatsuka M: Cbfa1 isoforms exert functional differences in osteoblast differentiation. J Biol Chem 1999;274:6972-6978.
42. Karsenty G: Role of Cbfa1 in osteoblast differentiation and function. Semin Cell Dev Biol 2000;11:343-346. (Pubitemid 32096083)
43. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H: PPAR γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004;113:846-855. (Pubitemid 38544143)
44. Cock TA, Back J, Elefteriou F, Karsenty G, Kastner P, Chan S, Auwerx J: Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep 2004;5:1007-1012. (Pubitemid 39534460)
45. Higuchi C, Myoui A, Hashimoto N, Kuriyama K, Yoshioka K, Yoshikawa H, Itoh K: Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J Bone Miner Res 2002;17:1785-1794.
46. Viñals F, López-Rovira T, Rosa JL, Ventura F: Inhibition of PI3K/p70 S6K and p38 MAPK cascades increases osteoblastic differentiation induced by BMP-2. FEBS Lett 2002;510:99-104. (Pubitemid 34084891)
47. Hu Y, Chan E, Wang SX, Li B: Activation of p38 mitogen activated protein kinase is required for osteoblast differentiation. Endocrinology 2003;144:2068-2074. (Pubitemid 36543347)
48. Zhou H, Yang X, Wang N, Zhang Y, Cai G: Tigogenin inhibits adipocytic differentiation and induces osteoblastic differentiation in mouse bone marrow stromal cells. Mol Cell Endocrinol 2007;270:17-22. (Pubitemid 46670545)
49. Hu E, Kim JB, Sarraf P, Spiegelman BM: Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 1996;274:2100-2103. (Pubitemid 27020707)
50. Aouadi M, Laurent K, Prot M, Le Marchand-Brustel Y, Binétruy B, Bost F: Inhibition of p38MAPK increases adipogenesis from embryonic to adult stages. Diabetes 2006;55:281-289. (Pubitemid 43343254)